Table 1 Comparison of baseline data, hematological parameters and coronary angiography data between elevated RBG group and control group
Variables | Elevated RBG group (n = 265) | Control group(n = 693) | P value |
|---|---|---|---|
Gender(man) | 193 (72.8%) | 551 (79.5%) | 0.026* |
Age | 64.08 ± 12.94 | 61.64 ± 13.47 | 0.019* |
Height(cm) | 166.71 ± 7.44 | 166.78 ± 7.54 | 0.92 |
Weight(kg) | 68.55 ± 12.18 | 68.76 ± 11.38 | 0.844 |
BMI(kg/m2) | 24.93 ± 3.87 | 24.44 ± 3.53 | 0.132 |
SBP(mmHg) | 124.80 ± 24.80 | 126.52 ± 20.83 | 0.315 |
DBP(mmHg) | 76.14 ± 16.29 | 76.98 ± 14.32 | 0.472 |
Hypertension | 167 (63.0%) | 384 (55.4%) | 0.033* |
Diabetes | 174 (65.7%) | 88 (12.7%) | < 0.001* |
Previous MI | 12 (4.5%) | 10 (1.4%) | 0.013* |
Cerebral infarction | 37 (14.0%) | 65 (9.4%) | 0.040* |
CKD | 30 (11.3%) | 49 (7.1%) | 0.032* |
Smoking | 119 (44.9%) | 380 (54.8%) | 0.006* |
Killip grade | |||
 I grade | 158 (59.6%) | 502 (72.4%) | < 0.001* |
 II grade | 42 (15.8%) | 112 (16.1%) | 0.906 |
 III grade | 2 (0.8%) | 9 (1.3%) | 0.480 |
 IV grade | 63 (23.8%) | 70 (10.1%) | < 0.001* |
TNI P50(P25-P75)(ng/ml) | 17.9 (3.2–25) | 14 (3.53–25) | 0.286 |
Myo P50(P25-P75) (ng/ml) | 500 (241–900) | 500 (239–900) | 0.096 |
CK-MB P50(P25-P75)(ng/ml) | 80 (26.9–292) | 80 (44–303.25) | 0.406 |
BNP P50(P25-P75) (pg/ml) | 216.5 (55.9–862) | 134 (43.3–393.25) | 0.002* |
WBC (*10^9/L) | 12.46 ± 4.61 | 11.19 ± 3.68 | < 0.001* |
Hb (g/L) | 133.21 ± 23.15 | 135.99 ± 20.71 | 0.098 |
PLT (*10^9/L) | 207.48 (146.4–289.3) | 204.68 (130.5–275.2) | 0.564 |
RBG(mmol/L) | 16.34 (13.2–20.6) | 7.35 (6.8–9.6) | < 0.001* |
ALT P50(P25-P75)IU/L) | 53 (34–82) | 44 (30–68.75) | 0.001* |
AST P50(P25-P75) (IU/L) | 174.5 (79–323) | 157.5 (76.75–262.25) | 0.073 |
Scr P50(P25-P75) (μmol/L) | 81 (71–105.5) | 80.5 (69–92) | 0.1 |
eGFR P50(P25-P75) (ml/min/1.73m2) | 77.18 (54.95–96.24) | 82.37 (68.89–97.27) | 0.022* |
UA(μmol/L) | 364.18 (318.3–468.6) | 366.75 (314.6–453.3) | 0.079 |
FBG(mmoL/L) | 12.00 ± 5.47 | 6.45 ± 2.02 | < 0.001* |
TG(mmoL/L) | 2.12 (1.68–3.39) | 1.67 (1.32–2.87) | 0.004* |
TC(mmoL/L) | 4.27 (3.03–5.97) | 4.48 (2.97–5.42) | 0.044* |
HDL-c(mmoL/L) | 1.02 (0.82–1.88) | 1.13 (1.01–1.96) | < 0.001* |
LDL-c(mmoL/L) | 2.62 (2.38–3.42) | 2.80 (2.07–3.36) | 0.017* |
LVEF (%) | 0.54 ± 0.12 | 0.58 ± 0.11 | < 0.0010* |
Aspirin | 263 (99.2%) | 681 (98.3%) | 0.26 |
Clopidogrel | 21 (7.9%) | 95 (13.7%) | 0.014* |
Ticagrelor | 244(%) | 598 (86.3%) | 0.014* |
ACEI/ARB | 112 (92.1%) | 370 (53.4%) | 0.002* |
β-blocker | 214 (80.8%) | 580 (83.7%) | 0.28 |
Statin | 265 (100%) | 688 (99.3%) | 0.166 |
CCB | 16 (6.0%) | 44 (6.3%) | 0.338 |
Furosemide | 72 (27.1%) | 177 (25.8%) | 0.424 |
Antisterone | 70 (26.4%) | 179(%) | 0.261 |
IABP | 28 (10.6%) | 35 (5.1%) | 0.002* |
CABG | 5 (1.9%) | 8 (1.2%) | 0.381 |
Coronary lesions | |||
 Single vessel lesion | 44 (16.6%) | 192 (27.7%) | < 0.001* |
 Double vessel lesions | 95 (35.8%) | 191 (27.6%) | 0.012* |
 Triple vessel lesions | 126 (47.5%) | 310 (44.7%) | 0.434 |
Number of stents | |||
 Single stent | 167 (63.0%) | 415 (59.9%) | 0.374 |
 Two or more stents | 44 (5.3%) | 133 (19.2%) | 0.356 |
 Left main lesion | 37 (14.0%) | 62 (9.0%) | 0.023* |